This study compared healing rates, relief of symptoms, frequency of adverse events, and proportion of patients in remission after one year follow up in 104 patients with active prepyloric ulcer during treatment with 40 mg omeprazole once daily or 2 g sucralfate twice daily, using a randomised double blind controlled trial. Healing rates after two, four, and six weeks were (omeprazole/sucralfate) 49%I 23%; 83%59%; 90%/70% respectively. After two weeks, omeprazole was more efficient than sucralfate in relief of daytime and nocturnal epigastric pain, nausea, and heartburn. The proportion of patients in remission after one year follow up was significantly higher in the omeprazole group (p<001). Of the healed patients ulcers recurred in 36% in the omeprazole group and in 46% in the sucralfate group. It is concluded that the ulcer healing rate was higher and symptom relief was more pronounced in the omeprazole group compared with the sucralfate group, and that more patients were still in remission after a one year follow up period.
six weeks were (omeprazole/sucralfate) 49%I 23%; 83%59%; 90%/70% respectively. After two weeks, omeprazole was more efficient than sucralfate in relief of daytime and nocturnal epigastric pain, nausea, and heartburn. The proportion of patients in remission after one year follow up was significantly higher in the omeprazole group (p<001). Of the healed patients ulcers recurred in 36% in the omeprazole group and in 46% in the sucralfate group. It is concluded that the ulcer healing rate was higher and symptom relief was more pronounced in the omeprazole group compared with the sucralfate group, and that more patients were still in remission after a one year follow up period. (Gut 1994; 35: 837-840) Treatment of patients with prepyloric gastric ulcer remains a therapeutic challenge. The healing rates are lower than among patients with ulcers located in duodenum and gastric body."A It is generally believed that prepyloric ulcers resemble duodenal ulcers with regard to acid secretory pattern.3 It has been found that omeprazole compared with cimetidine accelerates heal- Only two tailed tests were used. Tests of healing and confidence limits of healing rates are adjusted for the interim analysis to have an overall significance value of 5%.
The primary efficacy variable was endoscopic ulcer healing and the data were subjected to both a 'per protocol analysis' -including only patients who completed an assessment period according to the protocol and an 'intention to treat analysis' -including all patients who entered the study. Patients lost to follow up were considered unhealed in the formal tests of healing when using the 'intention to treat' approach.
In the follow up study survival curves were estimated according to the lifetable method. The SAS procedure lifetest has been used to estimate the survival curves and the log rank test was used to compare the two treatment groups.
The variable under analysis was time in uninterrupted remission or the time to first relapse. As withdrawal of patients. There were five treatment failures, all in the sucralfate group. The treatment groups were well matched for selected patient characteristics (Table II) .
ULCER HEALING Table III shows the healing rates in the two treatment groups for each of the two cohorts, in addition to the 98-6% (adjusting the 95% limit for the effect of interim analysis according to O'Brien and Flemming) confidence limits for the differences in healing rates between the groups. In both analytical cohorts and on all study days the cumulative healing rates were higher in the omeprazole group than in the sucralfate group. A survival type test was not performed because we did not want to overlook a possible superior effect of sucralfate after a two week treatment period.
ULCER PAIN Table IV compares the duration of symptoms during the last two days in the two groups. At day 15 omeprazole was more efficient than sucralfate in relief of daytime and nocturnal epigastric pain (standard x) test, p=O0-002 and p=0 04 respectively), nausea (Mantel-Haenzel test, p=0 0004), and heartburn (MantelHaenzel test, p=0 003).
UNEXPECTED SYMPTOMS AND LABORATORY FINDINGS
Three patients (one in the omeprazole group) were withdrawn because of intercurrent disease (heart attack, vomiting, and inability to take oral medication, raised alkaline phosphatase activity because of a gall stone), none were related to the study treatment. In the omeprazole group three patients reported transient headaches, one dizziness, one diarrhoea, two constipation. In the sucralfate group one patient reported nausea and one influenza.
In several cases a single laboratory value fell outside the reference range, but such abnormalities occurred at random in both treatment groups, and none of these abnormalities could be related to the study treatment.
FOLLOW UP STUDY
A total of 51 patients from the omeprazole group and 44 from the sucralfate group entered the follow up study. Nine patients from the sucralfate group and two from the omeprazole group were excluded from survival analysis because of non-compliance and loss to follow up.
At the end of the follow up period the estimated proportion of patients with ulcer relapse was, according to the survival curve, 64 per cent in the sucralfate group and 42 per cent in the omeprazole group (Fig 1) . A log rank test gave x2=6 64 (p=001) and hence rejected the hypothesis of equal treatment effects. Thus, the pattern of remission was more favourable among the omeprazole treated patients than among the patients treated with sucralfate. The proportion of patients with ulcer relapse after 360 days was Discussion This is the first study comparing omeprazole in the treatment of peptic ulcer with a non-acid inhibiting agent. We found that omeprazole is superior to sucralfate in accelerating ulcer healing and bringing pain relief. The study was stopped after the first interim analysis.
In accordance with other studies, there was a poor correlation between healing and pain relief.' 241011 Most patients in both groups were free from pain after two weeks. The results confirm the effect of omeprazole on prepyloric ulcers. The healing rates in the omeprazole group are of the same magnitude as in a previous study4 in contrast with sucralfate, which had lower healing rates than cimetidine. This, benefit was obtained without serious adverse events. The differences seen in healing rates and frequencies of patients without pain and the 95% confidence limits for the therapeutic gain are possibly of clinical importance. The benefit is less discernible than in patients with duodenal ulcer although it is generally believed that prepyloric ulcers resemble duodenal ulcers with regard to acid secretory pattern. 3 In the follow up study only symptomatic patients had an endoscopy. The relapse rate might have been higher if the asymptomatic patients were included. The follow up study showed that more patients were in remission in the omeprazole group than in the sucralfate group after 12 months. This difference was related to the primary healing rates. There was no significant difference in the proportion of patients with ulcer relapse when only those patients with healed ulcers at end of active treatment were considered. Omeprazole healed a greater proportion of patients, however, than sucralfate, and, being more effective, omeprazole also healed the more severe cases and these might have been more prone to relapse. This has, however, not been shown. Thus the group of patients healed by omeprazole is not comparable with the group of patients healed by sucralfate regarding time in remission and relapse time. 2 In conclusion, omeprazole was shown to heal a higher proportion of patients, provided more pronounced symptom relief, and resulted in more patients in remission during 12 months after treatment was stopped compared with sucralfate in patients with prepyloric ulcer. 
